Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in proliferative lupus nephritis and IgA nephropathy
NCT04564339Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2021
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of ravulizumab in lupus nephritis (LN), IgA nephropathy (IgAN), sponsored by Alexion Pharmaceuticals. Started Jan 2021; status: terminated.
02
Drugs
ravulizumab
03
Conditions
lupus nephritis (LN)IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT04564339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04564339.